Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 1, 1999
Last updated: February 1, 2013
Last verified: April 2002
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2004
  Estimated Primary Completion Date: No date given